aap Announces Exploration of Strategic Alternatives to Create More Value
aap Implantate AG (XETRA: AAQ) (“aap” or the “Company”), a globally operating medical device company headquartered in Be…
aap Implantate AG (XETRA: AAQ) (“aap” or the “Company”), a globally operating medical device company headquartered in Be…
aap Implantate AG (“aap”) posted sales and EBITDA in line with the guidance in the second quarter of 2017 and thereby ac…
aap Implantate AG ("aap") announces that in course of drawing up the annual financial statements for 2016 the Management…
aap Implantate AG (XETRA: AAQ.DE), a developer, manufacturer, and distributor of innovative trauma products and biomater…
aap Implantate AG aims to continue implementing its growth strategy in financial year 2015. The company plans growth in…
aap Implantate AG (XETRA: AAQ.DE), a developer, manufacturer and distributor of innovative trauma products, announced th…
aap Implantate AG sales revenues totalled EUR 7.8 million in the third quarter of 2014 (previous year, continuing operat…
aap realized in the second quarter of 2014 sales of EUR 8.1 million (previous year: continued business operations EUR 6.…
aap gives notice that its subsidiary aap Biomaterials GmbH signed a supply agreement for a PMMA bone cement with a leadi…
aap Implantate AG (XETRA: AAQ.DE) reports, on the basis of preliminary figures, first quarter 2014 sales of EUR 7.1 mill…